Evidence map›Paper›PMID 38820260›Full record

ArticlePloS one2024

Determinants of sputum culture conversion time in multidrug-resistant tuberculosis patients in ALERT comprehensive specialized hospital, Addis Ababa, Ethiopia: A retrospective cohort study.

Muluye Abebe, Abay Atnafu, Melaku Tilahun, Nejmia Sero, Sebisib Neway, Mekdes Alemu, Getachew Tesfaye, Adane Mihret, Kidist Bobosha, Chengsong Wan

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Muluye AbebeSchool of Public Health, Southern Medical University, Guangzhou, China.
Abay AtnafuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID 0000-0001-7594-4004
Melaku TilahunArmauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID 0000-0002-3101-3926
Nejmia SeroAll Africa Leprosy, Tuberculosis and Rehabilitation Training Center (ALERT) Specialized Hospital, Addis Ababa, Ethiopia.
Sebisib NewayArmauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID 0000-0002-2033-5874
Mekdes AlemuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID 0000-0002-5860-7070
Getachew TesfayeArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Adane MihretArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Kidist BoboshaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Chengsong WanSchool of Public Health, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe treatment response of multi-drug resistance tuberculosis (MDR-Tuberculosis) patients is mainly dictated by the sputum culture conversion. An earlier culture conversion is a remarkable indicator of the improvement in the treatment response. In this study, we aimed to determine the time to culture conversion and its associated factors among MDR-Tuberculosis patients in All Africa Leprosy, Tuberculosis and Rehabilitation Training Center (ALERT) Hospital, Addis Ababa, Ethiopia.

methodsA retrospective cohort study was conducted on 120 MDR-Tuberculosis patients attending ALERT Hospital from 2018-2022. Kaplan-Meier methods were used to determine the time to initial sputum culture conversion. All relevant laboratory, socio-demographic characteristics, and other clinical data were collected by chart abstraction using a structure data extraction form. The log-rank test was used to determine the survival rate. To identify the predictors of culture conversion, bivariate and multivariate Cox proportional hazard regression analysis was used. The hazard ratio (HR) with a 95% confidence interval was used to estimate the effect of each variable on the initial culture conversion. A test with a P value of < 0.05 was considered statistically significant.

resultsFrom the total of 120 study participants, 89.2% (107/120) have shown a successful culture conversion. The median age of the participants was 30 years (IQR = 12). The study participants were followed for 408.6 person-months (34.05 person-years). The median time to initial sputum culture conversion was 80 days. The median time to initial sputum culture conversion among HIV-positive and HIV-negative participants was 61 days (IQR = 58-63.5) and 88 days (IQR = 75-91), respectively. HIV-negative and patients with previous treatment history were shown to be the predictor for a prolonged time to initial sputum culture conversion, (aHR = 0.24 (95% CI: 0.1-0.4), P value <0.001) and (aHR = 0.47 (95% CI: 0.31-0.71), P value <0.001) respectively.

conclusionThe median time to sputum culture conversion for HIV positive was found to be 61 days in our study. Notably, patients with a history of previous anti-tuberculosis treatment, HIV-negative status, and higher bacillary load at baseline exhibited delayed culture conversion. These findings underscore the importance of considering such patient characteristics in the management of MDR-TB cases, as tailored interventions and close monitoring may lead to more favorable treatment outcomes. By identifying individuals with these risk factors early in the treatment process, healthcare providers can implement targeted strategies to optimize patient care and improve overall treatment success rates in MDR-TB management programs.

Indexed as

Antitubercular AgentsSputumTuberculosis, Multidrug-ResistantAdultEthiopiaFemaleHospitals, SpecialHumansMaleMiddle AgedMycobacterium tuberculosisProportional Hazards ModelsRetrospective StudiesYoung AdultAntitubercular Agents

Identifiers

PMID38820260
PMCPMC11142444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.